Literature DB >> 31588121

Importance of gastric cancer for the diagnosis and surveillance of Japanese Lynch syndrome patients.

Tsuneo Ikenoue1, Masami Arai2, Chikashi Ishioka2, Takeo Iwama2, Satoshi Kaneko2, Nagahide Matsubara2, Yoshihiro Moriya2, Tadashi Nomizu2, Kokichi Sugano2, Kazuo Tamura2, Naohiro Tomita2, Teruhiko Yoshida2, Kenichi Sugihara2, Hiromu Naruse1, Kiyoshi Yamaguchi1, Masanori Nojima3, Yusuke Nakamura4, Yoichi Furukawa5,6.   

Abstract

Lynch syndrome (LS) is an autosomal dominantly inherited disease predisposed to not only colorectal cancer but also other LS-related tumors. Although the clinical and genetic characteristics of LS in Western countries have been well characterized, the information of Japanese LS is limited. As a collaborative study of Japanese Society for Cancer of the Colon and Rectum (JSCCR), we registered colorectal cancer (CRC) patients who fulfilled the modified Amsterdam II criteria including gastric cancer as an LS-related tumor. Among 4030 CRC patients initially registered in this project, 85 patients (2.1%) fulfilled the modified criteria. An additional 26 patients who met the same criteria were enrolled in the analysis. We analyzed three major responsible genes, MLH1, MSH2, and MSH6 by direct sequencing, and further performed multiplex ligation-dependent probe amplification for MLH1 and MSH2. Consequently, we identified pathogenic variants in 64 of the 111 patients comprising of 34 patients in MLH1, 28 in MSH2, and 2 in MSH6. It is of note that large structural alterations were found in 17 patients. Among the 64 patients, 11 patients would not have been enrolled in the analysis if gastric cancer were not included in the modified criteria. In addition, 10 of the 64 variant carriers (15.6%) had medical history of gastric cancer. Furthermore, the standardized incidence ratio of gastric cancer in the LS patients to the Japanese population is estimated to be as high as 20.2. These data underscore the importance of gastric cancer in the diagnosis and healthcare of Japanese LS patients.

Entities:  

Mesh:

Year:  2019        PMID: 31588121     DOI: 10.1038/s10038-019-0674-5

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  2 in total

1.  Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea.

Authors:  Y J Park; K H Shin; J G Park
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

Review 2.  Genetic susceptibility to non-polyposis colorectal cancer.

Authors:  H T Lynch; A de la Chapelle
Journal:  J Med Genet       Date:  1999-11       Impact factor: 6.318

  2 in total
  5 in total

1.  Genetic Gastric Cancer Risk Syndromes.

Authors:  Benjamin A Lerner; Xavier Llor
Journal:  Curr Treat Options Gastroenterol       Date:  2020-10-19

Review 2.  Overview on population screening for carriers with germline mutations in mismatch repair (MMR) genes in China.

Authors:  Min Zhang; Tianhui Chen
Journal:  Hered Cancer Clin Pract       Date:  2021-05-01       Impact factor: 2.164

3.  Upper Gastrointestinal Lesions during Endoscopy Surveillance in Patients with Lynch Syndrome: A Multicentre Cohort Study.

Authors:  Romain Chautard; David Malka; Elia Samaha; David Tougeron; Didier Barbereau; Olivier Caron; Gabriel Rahmi; Thierry Barrioz; Christophe Cellier; Sandrine Feau; Thierry Lecomte
Journal:  Cancers (Basel)       Date:  2021-04-01       Impact factor: 6.639

4.  Characteristics of Li-Fraumeni Syndrome in Japan; A Review Study by the Special Committee of JSHT.

Authors:  Michinori Funato; Yukiko Tsunematsu; Fumito Yamazaki; Chieko Tamura; Tadashi Kumamoto; Masatoshi Takagi; Shunsuke Kato; Haruhiko Sugimura; Kazuo Tamura
Journal:  Cancer Sci       Date:  2021-05-01       Impact factor: 6.716

Review 5.  Endoscopic Surveillance in Patients with the Highest Risk of Gastric Cancer: Challenges and Solutions.

Authors:  Jessica M Long; Jessica Ebrahimzadeh; Peter P Stanich; Bryson W Katona
Journal:  Cancer Manag Res       Date:  2022-10-10       Impact factor: 3.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.